Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.11 Per Share

Equities research analysts forecast that Compugen Ltd. (NASDAQ:CGEN) will post earnings per share (EPS) of ($0.11) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Compugen’s earnings, with estimates ranging from ($0.12) to ($0.10). Compugen posted earnings per share of ($0.14) in the same quarter last year, which would suggest a positive year over year growth rate of 21.4%. The company is expected to report its next earnings results on Monday, May 18th.

According to Zacks, analysts expect that Compugen will report full year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts anticipate that the business will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.55) to ($0.44). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Compugen.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01.

A number of equities research analysts have issued reports on the stock. BidaskClub downgraded shares of Compugen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective (up from $10.00) on shares of Compugen in a research report on Friday, February 21st. ValuEngine raised shares of Compugen from a “sell” rating to a “hold” rating in a research report on Friday, January 24th. SunTrust Banks initiated coverage on shares of Compugen in a research report on Tuesday. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Compugen from a “hold” rating to a “sell” rating in a research report on Monday, March 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $11.75.

CGEN stock traded up $0.34 during trading on Friday, reaching $7.48. The stock had a trading volume of 1,306,500 shares, compared to its average volume of 839,267. Compugen has a one year low of $2.73 and a one year high of $12.80. The company’s 50 day moving average is $8.80 and its two-hundred day moving average is $6.18. The company has a market capitalization of $485.78 million, a price-to-earnings ratio of -17.00 and a beta of 2.17.

Several institutional investors have recently added to or reduced their stakes in CGEN. State Street Corp purchased a new position in Compugen in the third quarter worth about $92,000. Phoenix Holdings Ltd. acquired a new position in Compugen in the 3rd quarter valued at about $225,000. Janney Montgomery Scott LLC grew its position in Compugen by 42.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 6,900 shares in the last quarter. Rothschild Investment Corp IL grew its position in Compugen by 2.4% in the 4th quarter. Rothschild Investment Corp IL now owns 342,051 shares of the biotechnology company’s stock valued at $2,039,000 after acquiring an additional 8,050 shares in the last quarter. Finally, ARK Investment Management LLC grew its position in Compugen by 3.3% in the 4th quarter. ARK Investment Management LLC now owns 8,975,310 shares of the biotechnology company’s stock valued at $53,493,000 after acquiring an additional 283,993 shares in the last quarter. 33.74% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Recommended Story: How to build a Fibonacci channel

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.